A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)

NCT05282953 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Retinitis Pigmentosa
Choroideremia
Non-Syndromic Rod-Dominant Inherited Retinal Diseases

Interventions

DRUG: KIO-301

Sponsor

Kiora Pharmaceuticals, Inc.